Craig Matturro

Craig Matturro joined 1315 Capital in 2016 after two years as an Analyst in the Investment Banking Group of Leerink Partners, LLC, where he worked on multiple M&A and private placement engagements for small to mid-cap public and private companies across all healthcare subsectors.

During his time at 1315 Capital, Craig went on secondment to serve as Director of Business Development for 1315 Capital portfolio company, JDS Therapeutics, where he led the divesture of the Company’s Nutrition21 division to Everwell Health, as well as the acquisition of patented nutraceutical assets by the Company’s Bonafide Health division (acquired by Pharmavite).

Craig currently serves on the board of Restorative Therapies, SciSafe, Spineology, and Triple Ring Technologies, and is a board observer for Innovative Health and Onkos Surgical, and previously was a board observer for Solsys Medical (acquired by Misonix) and Centurion Service Group (acquired by TRIMEDX).

Craig received a BSc from Carnegie Mellon University in Business Administration – Concentration in Finance with University Honors, and a minor in Engineering Studies.